AxoGen (AXGN) Financials

$17.13 +0.65 (+3.94%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$17.56 +0.43 (+2.52%)

As of 05/2/2025 07:59 PM Eastern

Annual Income Statements for AxoGen

This table shows AxoGen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-29	-22	-9.96
Consolidated Net Income / (Loss)	-29	-22	-9.96
Net Income / (Loss) Continuing Operations	-29	-22	-9.96
Total Pre-Tax Income	-29	-22	-9.96
Total Operating Income	-30	-21	-3.29
Total Gross Profit	109	122	142
Total Revenue	139	159	187
Operating Revenue	139	159	187
Total Cost of Revenue	30	37	45
Operating Cost of Revenue	30	37	45
Total Operating Expenses	139	143	145
Selling, General & Admin Expense	41	38	39
Marketing Expense	72	78	78
Research & Development Expense	26	27	28
Total Other Income / (Expense), net	0.76	-0.25	-6.68
Interest Expense	0.62	2.84	8.21
Interest & Investment Income	0.57	1.49	1.14
Other Income / (Expense), net	0.81	1.09	0.39
Basic Earnings per Share	($0.69)	($0.51)	($0.23)
Weighted Average Basic Shares Outstanding	42.08M	42.88M	44.26M
Diluted Earnings per Share	($0.69)	($0.51)	($0.23)
Weighted Average Diluted Shares Outstanding	42.08M	42.88M	44.26M
Weighted Average Basic & Diluted Shares Outstanding	42.60M	43.21M	44.34M

This table shows AxoGen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-4.32	-5.42	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Consolidated Net Income / (Loss)	-4.32	-5.42	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Net Income / (Loss) Continuing Operations	-4.32	-5.38	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Total Pre-Tax Income	-4.32	-5.38	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Total Operating Income	-4.86	-5.61	-7.34	-6.90	-4.03	-3.19	-4.56	-0.43	-0.32	2.02
Total Gross Profit	31	24	28	30	32	32	33	35	36	38
Total Revenue	37	36	37	38	41	43	41	48	49	49
Operating Revenue	37	36	37	38	41	43	41	48	49	49
Total Cost of Revenue	6.18	12	8.17	8.50	9.57	11	8.76	13	12	12
Operating Cost of Revenue	6.18	12	8.17	8.50	9.57	11	8.76	13	12	12
Total Operating Expenses	36	30	36	37	36	35	37	36	37	36
Selling, General & Admin Expense	8.80	13	10	11	9.87	7.93	9.96	9.42	11	8.83
Marketing Expense	20	12	19	19	19	20	20	20	19	20
Research & Development Expense	7.05	5.28	6.33	7.14	6.69	7.18	7.41	6.66	7.00	6.70
Total Other Income / (Expense), net	0.54	0.19	0.27	0.24	-0.06	-0.70	-2.08	-1.49	-1.54	-1.57
Interest Expense	0.06	-0.04	0.02	0.15	0.83	1.84	2.33	2.19	1.89	1.80
Interest & Investment Income	0.19	-	0.55	0.24	0.37	0.34	0.29	0.23	0.39	0.24
Weighted Average Basic Shares Outstanding	42.22M	42.08M	42.57M	42.86M	43.02M	42.88M	43.23M	43.71M	43.88M	44.26M
Weighted Average Diluted Shares Outstanding	42.22M	42.08M	42.57M	42.86M	43.02M	42.88M	43.23M	43.71M	43.88M	44.26M
Weighted Average Basic & Diluted Shares Outstanding	42.29M	42.60M	42.83M	42.98M	43.04M	43.21M	43.70M	43.83M	44.01M	44.34M

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-17	15	-3.47
Net Cash From Operating Activities	-16	-5.72	4.54
Net Cash From Continuing Operating Activities	-16	-5.72	4.54
Net Income / (Loss) Continuing Operations	-29	-22	-9.96
Consolidated Net Income / (Loss)	-29	-22	-9.96
Depreciation Expense	2.83	4.22	6.47
Amortization Expense	2.92	2.23	2.26
Non-Cash Adjustments To Reconcile Net Income	13	11	15
Changes in Operating Assets and Liabilities, net	-5.95	-1.16	-8.86
Net Cash From Investing Activities	-3.20	19	-10
Net Cash From Continuing Investing Activities	-3.20	19	-10
Purchase of Property, Plant & Equipment	-20	-14	-3.10
Acquisitions	-1.18	-1.05	-1.42
Purchase of Investments	-39	-10	-5.77
Sale and/or Maturity of Investments	57	44	0.00
Net Cash From Financing Activities	1.79	1.95	2.29
Net Cash From Continuing Financing Activities	1.79	1.95	2.29
Repayment of Debt	-0.01	-0.01	-0.01
Issuance of Common Equity	1.81	1.96	2.30
Cash Interest Paid	0.00	1.94	7.30

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	2.50	0.97	-7.58	16	7.63	-0.07	-15	3.48	-0.53	8.89
Net Cash From Operating Activities	-0.69	1.36	-7.42	0.29	1.63	-0.21	-12	4.17	3.90	8.74
Net Cash From Continuing Operating Activities	-0.69	1.36	-7.42	0.29	1.63	-0.21	-12	4.17	3.90	8.74
Net Income / (Loss) Continuing Operations	-4.32	-5.42	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Consolidated Net Income / (Loss)	-4.32	-5.42	-7.07	-6.66	-4.09	-3.89	-6.64	-1.92	-1.86	0.45
Depreciation Expense	0.76	0.65	0.71	0.80	1.15	1.56	1.52	1.66	1.65	1.64
Amortization Expense	0.74	0.75	0.75	0.47	0.48	0.52	0.60	0.63	0.54	0.50
Non-Cash Adjustments To Reconcile Net Income	3.28	2.14	2.49	5.28	2.69	0.26	4.11	5.28	2.11	3.14
Changes in Operating Assets and Liabilities, net	-1.15	3.25	-4.30	0.40	1.40	1.34	-12	-1.48	1.46	3.01
Net Cash From Investing Activities	2.97	-1.21	-0.79	14	5.99	-0.28	-3.25	-1.23	-5.00	-0.81
Net Cash From Continuing Investing Activities	2.97	-1.21	-0.79	14	5.99	-0.28	-3.25	-1.23	-5.00	-0.81
Purchase of Property, Plant & Equipment	-4.37	-6.62	-4.30	-4.42	-3.69	-1.46	-0.92	-0.91	-0.60	-0.67
Acquisitions	-0.18	-0.15	-0.25	-0.26	-0.22	-0.31	-0.42	-0.32	-0.54	-0.14
Net Cash From Financing Activities	0.22	0.81	0.63	0.90	0.01	0.42	0.20	0.54	0.57	0.97
Net Cash From Continuing Financing Activities	0.22	0.81	0.63	0.90	0.01	0.42	0.20	0.54	0.57	0.97
Repayment of Debt	-0.01	-0.00	-0.00	-0.01	0.01	-0.00	-0.00	-0.00	-0.00	-0.00
Issuance of Common Equity	0.22	0.82	0.63	0.91	-	0.42	0.21	0.55	0.57	0.97
Cash Interest Paid	-	-	0.00	-	0.33	1.62	1.66	2.10	1.98	1.57

This table presents AxoGen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	195	197	204
Total Current Assets	98	88	99
Cash & Equivalents	15	31	28
Restricted Cash	6.25	6.00	6.00
Short-Term Investments	34	0.00	5.93
Accounts Receivable	22	25	24
Inventories, net	19	23	33
Prepaid Expenses	1.94	2.81	2.45
Plant, Property, & Equipment, net	79	89	85
Total Noncurrent Assets	18	20	20
Intangible Assets	3.65	4.53	5.58
Other Noncurrent Operating Assets	14	16	14
Total Liabilities & Shareholders' Equity	195	197	204
Total Liabilities	94	101	100
Total Current Liabilities	24	30	31
Accounts Payable	22	29	29
Other Current Liabilities	1.31	1.55	1.97
Total Noncurrent Liabilities	71	71	69
Long-Term Debt	46	47	47
Capital Lease Obligations	20	21	19
Other Noncurrent Operating Liabilities	4.52	2.99	2.49
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	101	96	104
Total Preferred & Common Equity	101	96	104
Total Common Equity	101	96	104
Common Stock	361	377	395
Retained Earnings	-260	-281	-291

This table presents AxoGen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	196	189	192	195	187	189	192
Total Current Assets	102	89	86	87	79	82	86
Cash & Equivalents	14	7.71	23	31	16	19	19
Restricted Cash	6.25	6.25	6.25	6.00	6.00	6.00	6.00
Short-Term Investments	39	30	11	1.49	1.92	1.94	5.87
Accounts Receivable	21	22	22	23	24	25	25
Inventories, net	19	20	21	23	28	28	29
Prepaid Expenses	2.61	2.45	2.58	2.57	3.18	1.96	1.73
Plant, Property, & Equipment, net	75	83	87	89	88	87	86
Total Noncurrent Assets	18	18	18	18	20	20	20
Intangible Assets	3.45	3.86	4.05	4.29	4.77	4.97	5.22
Other Noncurrent Operating Assets	15	14	14	14	15	15	15
Total Liabilities & Shareholders' Equity	196	189	192	195	187	189	192
Total Liabilities	94	92	94	97	93	93	93
Total Current Liabilities	24	21	24	27	23	23	23
Accounts Payable	22	20	23	26	21	22	21
Other Current Liabilities	1.53	1.05	1.04	1.10	1.64	1.75	1.86
Total Noncurrent Liabilities	71	71	71	70	70	70	70
Long-Term Debt	45	46	46	46	47	47	47
Capital Lease Obligations	-	-	-	-	21	20	20
Other Noncurrent Operating Liabilities	25	25	24	24	2.92	2.55	2.54
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	101	98	97	98	93	96	99
Total Preferred & Common Equity	101	98	97	98	93	96	99
Total Common Equity	101	98	97	98	93	96	99
Common Stock	356	364	370	375	381	386	391
Retained Earnings	-254	-267	-273	-277	-288	-290	-292

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	8.81%	14.74%	17.81%
EBITDA Growth	-14.88%	39.85%	141.88%
EBIT Growth	-12.33%	29.51%	85.77%
NOPAT Growth	-16.88%	27.75%	84.68%
Net Income Growth	-7.27%	24.98%	54.12%
EPS Growth	-6.15%	26.09%	54.90%
Operating Cash Flow Growth	-19.85%	64.42%	179.34%
Free Cash Flow Firm Growth	-11.53%	34.88%	75.93%
Invested Capital Growth	27.60%	12.77%	3.76%
Revenue Q/Q Growth	3.45%	4.44%	3.58%
EBITDA Q/Q Growth	-2.90%	22.97%	326.24%
EBIT Q/Q Growth	-1.70%	14.55%	60.29%
NOPAT Q/Q Growth	-0.87%	10.11%	61.32%
Net Income Q/Q Growth	-0.45%	6.55%	30.36%
EPS Q/Q Growth	-1.47%	10.53%	25.81%
Operating Cash Flow Q/Q Growth	15.18%	-37.97%	202.81%
Free Cash Flow Firm Q/Q Growth	-0.71%	15.57%	80.52%
Invested Capital Q/Q Growth	27.98%	19.68%	-3.49%
Profitability Metrics	-	-	-
Gross Margin	78.51%	76.64%	75.79%
EBITDA Margin	-16.70%	-8.76%	3.11%
Operating Margin	-21.44%	-13.50%	-1.75%
EBIT Margin	-20.85%	-12.81%	-1.55%
Profit (Net Income) Margin	-20.89%	-13.66%	-5.32%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	100.19%	106.62%	343.70%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-20.80%	-12.60%	-1.79%
ROIC Less NNEP Spread (ROIC-NNEP)	98.73%	-44.63%	-28.23%
Return on Net Nonoperating Assets (RNNOA)	-6.31%	-9.48%	-8.20%
Return on Equity (ROE)	-27.11%	-22.08%	-9.99%
Cash Return on Invested Capital (CROIC)	-45.06%	-24.60%	-5.48%
Operating Return on Assets (OROA)	-14.32%	-10.39%	-1.45%
Return on Assets (ROA)	-14.35%	-11.07%	-4.98%
Return on Common Equity (ROCE)	-27.11%	-22.08%	-9.99%
Return on Equity Simple (ROE_SIMPLE)	-28.66%	-22.70%	-9.59%
Net Operating Profit after Tax (NOPAT)	-21	-15	-2.30
NOPAT Margin	-15.01%	-9.45%	-1.23%
Net Nonoperating Expense Percent (NNEP)	-119.54%	32.03%	26.45%
Return On Investment Capital (ROIC_SIMPLE)	-12.44%	-9.19%	-1.35%
Cost of Revenue to Revenue	21.49%	23.36%	24.21%
SG&A Expenses to Revenue	29.52%	24.16%	20.84%
R&D to Revenue	18.49%	17.19%	14.82%
Operating Expenses to Revenue	99.95%	90.14%	77.54%
Earnings before Interest and Taxes (EBIT)	-29	-20	-2.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-23	-14	5.83
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.18	3.07	6.98
Price to Tangible Book Value (P/TBV)	4.34	3.23	7.38
Price to Revenue (P/Rev)	3.05	1.85	3.87
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.86	2.57	5.74
Enterprise Value to Revenue (EV/Rev)	3.13	2.04	4.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	129.05
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	165.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.65	0.71	0.64
Long-Term Debt to Equity	0.65	0.71	0.64
Financial Leverage	-0.06	0.21	0.29
Leverage Ratio	1.89	1.99	2.01
Compound Leverage Factor	1.89	2.13	6.90
Debt to Total Capital	39.56%	41.46%	39.10%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.56%	41.46%	39.10%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.44%	58.54%	60.90%
Debt to EBITDA	-2.86	-4.87	11.44
Net Debt to EBITDA	-0.48	-2.21	4.67
Long-Term Debt to EBITDA	-2.86	-4.87	11.44
Debt to NOPAT	-3.18	-4.51	-29.00
Net Debt to NOPAT	-0.53	-2.04	-11.84
Long-Term Debt to NOPAT	-3.18	-4.51	-29.00
Altman Z-Score	1.50	0.56	3.63
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	4.13	2.89	3.24
Quick Ratio	2.99	1.85	1.88
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-45	-29	-7.06
Operating Cash Flow to CapEx	-80.02%	-41.21%	146.24%
Free Cash Flow to Firm to Interest Expense	-72.18	-10.35	-0.86
Operating Cash Flow to Interest Expense	-25.75	-2.02	0.55
Operating Cash Flow Less CapEx to Interest Expense	-57.92	-6.91	0.17
Efficiency Ratios	-	-	-
Asset Turnover	0.69	0.81	0.94
Accounts Receivable Turnover	6.87	6.72	7.61
Inventory Turnover	1.67	1.77	1.61
Fixed Asset Turnover	1.95	1.89	2.16
Accounts Payable Turnover	1.33	1.45	1.58
Days Sales Outstanding (DSO)	53.13	54.32	47.98
Days Inventory Outstanding (DIO)	218.19	206.00	226.12
Days Payable Outstanding (DPO)	275.22	252.19	231.44
Cash Conversion Cycle (CCC)	-3.90	8.13	42.67
Capital & Investment Metrics	-	-	-
Invested Capital	112	126	131
Invested Capital Turnover	1.39	1.33	1.45
Increase / (Decrease) in Invested Capital	24	14	4.76
Enterprise Value (EV)	433	325	752
Market Capitalization	422	294	725
Book Value per Share	$2.39	$2.22	$2.36
Tangible Book Value per Share	$2.30	$2.12	$2.23
Total Capital	167	163	171
Total Debt	66	68	67
Total Long-Term Debt	66	68	67
Net Debt	11	31	27
Capital Expenditures (CapEx)	20	14	3.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)	19	21	29
Debt-free Net Working Capital (DFNWC)	74	58	69
Net Working Capital (NWC)	74	58	69
Net Nonoperating Expense (NNE)	8.15	6.69	7.66
Net Nonoperating Obligations (NNO)	11	31	27
Total Depreciation and Amortization (D&A)	5.74	6.44	8.73
Debt-free, Cash-free Net Working Capital to Revenue	13.91%	12.92%	15.55%
Debt-free Net Working Capital to Revenue	53.63%	36.21%	36.62%
Net Working Capital to Revenue	53.63%	36.21%	36.62%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.69)	($0.51)	($0.23)
Adjusted Weighted Average Basic Shares Outstanding	42.08M	42.88M	44.26M
Adjusted Diluted Earnings per Share	($0.69)	($0.51)	($0.23)
Adjusted Weighted Average Diluted Shares Outstanding	42.08M	42.88M	44.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.60M	43.21M	44.34M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-15	-2.30
Normalized NOPAT Margin	-15.01%	-9.45%	-1.23%
Pre Tax Income Margin	-20.89%	-13.66%	-5.32%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-46.30	-7.18	-0.35
NOPAT to Interest Expense	-33.33	-5.30	-0.28
EBIT Less CapEx to Interest Expense	-78.48	-12.08	-0.73
NOPAT Less CapEx to Interest Expense	-65.50	-10.19	-0.66
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	18.44%	14.67%	18.24%	10.74%	11.67%	18.69%	12.86%	25.57%	17.86%	15.10%
EBITDA Growth	45.68%	-17.13%	36.36%	10.11%	32.17%	93.11%	59.59%	142.35%	192.09%	1,453.75%
EBIT Growth	34.09%	-9.00%	31.31%	10.32%	18.32%	59.24%	39.50%	100.55%	90.33%	184.57%
NOPAT Growth	27.42%	-4.76%	35.15%	12.90%	17.10%	43.05%	37.88%	93.80%	92.15%	190.21%
Net Income Growth	39.53%	-2.44%	38.35%	13.95%	5.30%	28.11%	6.21%	71.16%	54.56%	111.56%
EPS Growth	41.18%	-7.69%	37.04%	11.11%	0.00%	42.86%	11.76%	75.00%	60.00%	0.00%
Operating Cash Flow Growth	-83.24%	189.96%	32.83%	105.13%	335.99%	-115.49%	-65.24%	1,326.37%	139.91%	4,239.81%
Free Cash Flow Firm Growth	-22,885.83%	-6.96%	-274.40%	-164.32%	24.21%	41.27%	-39.86%	-36.15%	-46.35%	83.43%
Invested Capital Growth	37.98%	27.60%	32.04%	24.01%	20.59%	12.77%	37.96%	32.49%	28.68%	3.76%
Revenue Q/Q Growth	7.27%	-2.15%	1.38%	4.07%	8.17%	4.00%	-3.60%	15.79%	1.53%	1.56%
EBITDA Q/Q Growth	51.67%	-51.43%	-37.82%	10.87%	63.53%	84.63%	-708.79%	193.40%	-20.70%	125.99%
EBIT Q/Q Growth	40.94%	-31.71%	-29.99%	11.31%	46.21%	34.28%	-92.96%	100.80%	-1,048.65%	674.64%
NOPAT Q/Q Growth	38.73%	-15.51%	-30.90%	5.98%	41.68%	20.65%	-42.77%	90.61%	26.17%	1,011.84%
Net Income Q/Q Growth	44.21%	-25.41%	-30.64%	5.85%	38.60%	4.79%	-70.43%	71.05%	3.28%	124.22%
EPS Q/Q Growth	44.44%	-40.00%	-21.43%	5.88%	37.50%	20.00%	-87.50%	73.33%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	87.89%	297.68%	-645.01%	103.93%	456.85%	-112.98%	-5,713.27%	133.96%	-6.34%	123.92%
Free Cash Flow Firm Q/Q Growth	-194.50%	-2.43%	-3.80%	15.58%	15.56%	20.63%	-147.19%	17.82%	9.23%	91.01%
Invested Capital Q/Q Growth	5.93%	27.98%	-11.38%	3.22%	3.00%	19.68%	8.42%	-0.87%	0.04%	-3.49%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	83.29%	67.46%	77.71%	77.71%	76.82%	74.60%	78.83%	73.77%	74.91%	76.05%
EBITDA Margin	-7.97%	-12.33%	-16.76%	-14.35%	-4.84%	-0.72%	-6.00%	4.84%	3.78%	8.41%
Operating Margin	-13.14%	-15.51%	-20.02%	-18.09%	-9.75%	-7.44%	-11.02%	-0.89%	-0.65%	4.08%
EBIT Margin	-12.02%	-16.18%	-20.75%	-17.68%	-8.79%	-5.56%	-11.12%	0.08%	-0.72%	4.08%
Profit (Net Income) Margin	-11.68%	-14.97%	-19.29%	-17.46%	-9.91%	-9.07%	-16.04%	-4.01%	-3.82%	0.91%
Tax Burden Percent	100.00%	100.59%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	97.19%	91.99%	92.99%	98.71%	112.68%	163.23%	144.18%	-5,191.89%	529.34%	22.31%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-16.31%	-15.05%	-23.16%	-20.23%	-10.76%	-6.95%	-10.69%	-0.91%	-0.68%	5.94%
ROIC Less NNEP Spread (ROIC-NNEP)	-13.51%	6.79%	-8.73%	6.56%	31.02%	-14.88%	-25.76%	-8.03%	-8.08%	0.53%
Return on Net Nonoperating Assets (RNNOA)	4.10%	-0.43%	1.16%	-0.45%	-0.95%	-3.16%	-6.17%	-1.90%	-1.81%	0.15%
Return on Equity (ROE)	-12.22%	-15.48%	-22.00%	-20.68%	-11.71%	-10.11%	-16.86%	-2.81%	-2.49%	6.09%
Cash Return on Invested Capital (CROIC)	-59.22%	-45.06%	-48.25%	-40.12%	-35.97%	-24.60%	-42.97%	-35.12%	-30.01%	-5.48%
Operating Return on Assets (OROA)	-7.94%	-11.12%	-15.45%	-13.49%	-6.86%	-4.51%	-9.69%	0.07%	-0.68%	3.82%
Return on Assets (ROA)	-7.72%	-10.29%	-14.36%	-13.32%	-7.73%	-7.35%	-13.97%	-3.66%	-3.57%	0.85%
Return on Common Equity (ROCE)	-12.22%	-15.48%	-22.00%	-20.68%	-11.71%	-10.11%	-16.86%	-2.81%	-2.49%	6.09%
Return on Equity Simple (ROE_SIMPLE)	-28.41%	0.00%	-25.17%	-24.15%	-23.76%	0.00%	-22.84%	-17.28%	-14.39%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.40	-3.93	-5.14	-4.83	-2.82	-2.24	-3.19	-0.30	-0.22	2.02
NOPAT Margin	-9.20%	-10.86%	-14.02%	-12.66%	-6.83%	-5.21%	-7.71%	-0.63%	-0.45%	4.08%
Net Nonoperating Expense Percent (NNEP)	-2.80%	-21.84%	-14.43%	-26.79%	-41.78%	7.93%	15.07%	7.12%	7.40%	5.41%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.35%	-	-	-	-1.37%	-	-	-	1.18%
Cost of Revenue to Revenue	16.71%	32.54%	22.29%	22.29%	23.18%	25.40%	21.17%	26.23%	25.09%	23.95%
SG&A Expenses to Revenue	23.80%	36.19%	27.44%	27.65%	23.92%	18.48%	24.06%	19.65%	22.27%	17.87%
R&D to Revenue	19.08%	14.60%	17.25%	18.72%	16.22%	16.72%	17.91%	13.90%	14.38%	13.57%
Operating Expenses to Revenue	96.43%	82.96%	97.73%	95.80%	86.57%	82.04%	89.85%	74.66%	75.56%	71.97%
Earnings before Interest and Taxes (EBIT)	-4.44	-5.85	-7.61	-6.75	-3.63	-2.39	-4.60	0.04	-0.35	2.02
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.94	-4.46	-6.14	-5.48	-2.00	-0.31	-2.48	2.32	1.84	4.16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.97	4.18	4.13	4.03	2.20	3.07	3.74	3.31	6.18	6.98
Price to Tangible Book Value (P/TBV)	5.14	4.34	4.30	4.20	2.30	3.23	3.94	3.49	6.52	7.38
Price to Revenue (P/Rev)	3.76	3.05	2.79	2.64	1.41	1.85	2.13	1.82	3.40	3.87
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.60	3.86	4.07	3.87	2.11	2.57	2.86	2.63	4.79	5.74
Enterprise Value to Revenue (EV/Rev)	3.66	3.13	2.80	2.68	1.46	2.04	2.40	2.06	3.60	4.02
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	475.86	129.05
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	165.93
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.45	0.65	0.47	0.48	0.47	0.71	0.72	0.70	0.67	0.64
Long-Term Debt to Equity	0.45	0.65	0.47	0.48	0.47	0.71	0.72	0.70	0.67	0.64
Financial Leverage	-0.30	-0.06	-0.13	-0.07	-0.03	0.21	0.24	0.24	0.22	0.29
Leverage Ratio	1.87	1.89	1.92	1.95	1.96	1.99	1.97	1.97	1.96	2.01
Compound Leverage Factor	1.82	1.74	1.79	1.92	2.21	3.26	2.84	-102.46	10.38	0.45
Debt to Total Capital	30.96%	39.56%	32.02%	32.21%	32.17%	41.46%	42.02%	41.28%	40.26%	39.10%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	30.96%	39.56%	32.02%	32.21%	32.17%	41.46%	42.02%	41.28%	40.26%	39.10%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.04%	60.44%	67.98%	67.79%	67.84%	58.54%	57.98%	58.72%	59.74%	60.90%
Debt to EBITDA	-2.02	-2.86	-2.34	-2.43	-2.57	-4.87	-6.58	-27.26	48.98	11.44
Net Debt to EBITDA	0.62	-0.48	-0.09	-0.28	-0.43	-2.21	-4.27	-16.27	26.66	4.67
Long-Term Debt to EBITDA	-2.02	-2.86	-2.34	-2.43	-2.57	-4.87	-6.58	-27.26	48.98	11.44
Debt to NOPAT	-2.21	-3.18	-2.55	-2.67	-2.77	-4.51	-5.16	-7.87	-11.26	-29.00
Net Debt to NOPAT	0.67	-0.53	-0.10	-0.31	-0.47	-2.04	-3.36	-4.70	-6.13	-11.84
Long-Term Debt to NOPAT	-2.21	-3.18	-2.55	-2.67	-2.77	-4.51	-5.16	-7.87	-11.26	-29.00
Altman Z-Score	2.49	1.89	1.71	1.53	0.43	0.86	1.23	1.18	3.19	3.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.35	4.13	4.18	3.60	3.28	2.89	3.43	3.51	3.74	3.24
Quick Ratio	3.16	2.99	2.83	2.34	2.10	1.85	1.82	1.98	2.13	1.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-28	-28	-29	-25	-21	-17	-41	-34	-31	-2.74
Operating Cash Flow to CapEx	-15.77%	20.57%	-172.47%	6.61%	44.07%	-14.42%	-1,327.49%	457.69%	653.43%	1,303.73%
Free Cash Flow to Firm to Interest Expense	-450.86	0.00	-1,827.54	-166.79	-25.21	-8.97	-17.58	-15.38	-16.12	-1.52
Operating Cash Flow to Interest Expense	-11.30	0.00	-463.94	1.97	1.97	-0.11	-5.27	1.91	2.06	4.85
Operating Cash Flow Less CapEx to Interest Expense	-82.93	0.00	-732.94	-27.86	-2.50	-0.91	-5.67	1.49	1.75	4.48
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.66	0.69	0.74	0.76	0.78	0.81	0.87	0.91	0.94	0.94
Accounts Receivable Turnover	6.71	6.87	7.06	7.05	6.82	6.72	7.04	7.43	7.55	7.61
Inventory Turnover	1.36	1.67	1.44	1.43	1.54	1.77	1.34	1.45	1.47	1.61
Fixed Asset Turnover	2.04	1.95	1.92	1.87	1.86	1.89	1.92	1.99	2.07	2.16
Accounts Payable Turnover	1.07	1.33	1.30	1.30	1.36	1.45	1.53	1.61	1.64	1.58
Days Sales Outstanding (DSO)	54.40	53.13	51.71	51.74	53.49	54.32	51.82	49.15	48.33	47.98
Days Inventory Outstanding (DIO)	269.22	218.19	253.91	254.68	237.46	206.00	273.17	251.16	248.78	226.12
Days Payable Outstanding (DPO)	340.34	275.22	279.89	281.57	268.07	252.19	238.60	227.22	221.92	231.44
Cash Conversion Cycle (CCC)	-16.73	-3.90	25.73	24.85	22.88	8.13	86.39	73.10	75.18	42.67
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	88	112	99	103	106	126	137	136	136	131
Invested Capital Turnover	1.77	1.39	1.65	1.60	1.58	1.33	1.39	1.46	1.50	1.45
Increase / (Decrease) in Invested Capital	24	24	24	20	18	14	38	33	30	4.76
Enterprise Value (EV)	490	433	404	396	223	325	393	357	651	752
Market Capitalization	504	422	403	391	215	294	349	316	614	725
Book Value per Share	$2.40	$2.39	$2.29	$2.27	$2.28	$2.22	$2.16	$2.19	$2.27	$2.36
Tangible Book Value per Share	$2.32	$2.30	$2.20	$2.17	$2.18	$2.12	$2.05	$2.08	$2.15	$2.23
Total Capital	147	167	143	143	144	163	161	163	166	171
Total Debt	45	66	46	46	46	68	68	67	67	67
Total Long-Term Debt	45	66	46	46	46	68	68	67	67	67
Net Debt	-14	11	1.81	5.37	7.79	31	44	40	36	27
Capital Expenditures (CapEx)	4.37	6.62	4.30	4.42	3.69	1.46	0.92	0.91	0.60	0.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)	20	19	23	21	22	21	32	32	33	29
Debt-free Net Working Capital (DFNWC)	79	74	67	62	61	58	56	59	63	69
Net Working Capital (NWC)	79	74	67	62	61	58	56	59	63	69
Net Nonoperating Expense (NNE)	0.92	1.49	1.94	1.83	1.27	1.66	3.44	1.62	1.64	1.57
Net Nonoperating Obligations (NNO)	-14	11	1.81	5.37	7.79	31	44	40	36	27
Total Depreciation and Amortization (D&A)	1.50	1.39	1.46	1.27	1.63	2.08	2.12	2.28	2.19	2.14
Debt-free, Cash-free Net Working Capital to Revenue	14.59%	13.91%	16.18%	14.51%	14.58%	12.92%	19.60%	18.28%	18.07%	15.55%
Debt-free Net Working Capital to Revenue	58.90%	53.63%	46.77%	42.07%	39.93%	36.21%	34.04%	33.92%	34.96%	36.62%
Net Working Capital to Revenue	58.90%	53.63%	46.77%	42.07%	39.93%	36.21%	34.04%	33.92%	34.96%	36.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	($0.14)	($0.17)	($0.16)	($0.10)	($0.08)	($0.15)	($0.04)	($0.04)	$0.00
Adjusted Weighted Average Basic Shares Outstanding	42.22M	42.08M	42.57M	42.86M	43.02M	42.88M	43.23M	43.71M	43.88M	44.26M
Adjusted Diluted Earnings per Share	($0.10)	($0.14)	($0.17)	($0.16)	($0.10)	($0.08)	($0.15)	($0.04)	($0.04)	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	42.22M	42.08M	42.57M	42.86M	43.02M	42.88M	43.23M	43.71M	43.88M	44.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	42.29M	42.60M	42.83M	42.98M	43.04M	43.21M	43.70M	43.83M	44.01M	44.34M
Normalized Net Operating Profit after Tax (NOPAT)	-3.40	-3.93	-5.14	-4.83	-2.82	-2.24	-3.19	-0.30	-0.22	1.41
Normalized NOPAT Margin	-9.20%	-10.86%	-14.02%	-12.66%	-6.83%	-5.21%	-7.71%	-0.63%	-0.45%	2.86%
Pre Tax Income Margin	-11.68%	-14.89%	-19.29%	-17.46%	-9.91%	-9.07%	-16.04%	-4.01%	-3.82%	0.91%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-72.84	0.00	-475.44	-45.59	-4.39	-1.29	-1.98	0.02	-0.19	1.12
NOPAT to Interest Expense	-55.71	0.00	-321.17	-32.64	-3.41	-1.21	-1.37	-0.14	-0.12	1.12
EBIT Less CapEx to Interest Expense	-144.48	0.00	-744.44	-75.42	-8.85	-2.09	-2.38	-0.40	-0.50	0.75
NOPAT Less CapEx to Interest Expense	-127.35	0.00	-590.17	-62.48	-7.87	-2.01	-1.77	-0.55	-0.43	0.75
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AxoGen's Financials

When does AxoGen's financial year end?

According to the most recent income statement we have on file, AxoGen's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has AxoGen's net income changed over the last 2 years?

AxoGen's net income appears to be on a downward trend, with a most recent value of -$9.96 million in 2024, falling from -$28.95 million in 2022. The previous period was -$21.72 million in 2023. Find out what analysts predict for AxoGen in the coming months.

What is AxoGen's operating income?

AxoGen's total operating income in 2024 was -$3.29 million, based on the following breakdown:

Total Gross Profit: $141.98 million
Total Operating Expenses: $145.26 million

How has AxoGen revenue changed over the last 2 years?

Over the last 2 years, AxoGen's total revenue changed from $138.58 million in 2022 to $187.34 million in 2024, a change of 35.2%.

How much debt does AxoGen have?

AxoGen's total liabilities were at $99.82 million at the end of 2024, a 1.3% decrease from 2023, and a 5.8% increase since 2022.

How much cash does AxoGen have?

In the past 2 years, AxoGen's cash and equivalents has ranged from $15.28 million in 2022 to $31.02 million in 2023, and is currently $27.55 million as of their latest financial filing in 2024.

How has AxoGen's book value per share changed over the last 2 years?

Over the last 2 years, AxoGen's book value per share changed from 2.39 in 2022 to 2.36 in 2024, a change of -1.1%.

Related Companies

This page (NASDAQ:AXGN) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Financials

Frequently Asked Questions About AxoGen's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AxoGen (AXGN) Financials

Annual Income Statements for AxoGen

Quarterly Income Statements for AxoGen

Annual Cash Flow Statements for AxoGen

Quarterly Cash Flow Statements for AxoGen

Annual Balance Sheets for AxoGen

Quarterly Balance Sheets for AxoGen

Annual Metrics and Ratios for AxoGen

Quarterly Metrics and Ratios for AxoGen

Frequently Asked Questions About AxoGen's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools